News

We are pleased to announce that the UltraGene Combo2Screen SARS-CoV-2 Assay has obtained Highly Satisfactory results (with a 100% accuracy for qualitative detection of all QCMD blinded samples, including with lowest viral load) in the context of the QCMD 2020 Coronavirus Outbreak Preparedness EQA Pi…

Optimizing COVID-19 management through highly sensitive SARS-CoV-2 detection test. Luxembourg (Luxembourg), Metz (France) — May 21— Advanced Biological Laboratories (ABL) announced today the CE-IVD registration of its UltraGene® Combo2Screen SARS-CoV-2 assay, now available for in-vitro diagnostics u…

A unique and flexible solution adapted to all virology and microbiology laboratories   LUXEMBOURG CITY (Luxembourg), METZ (France) — May 18th, 2020 — Advanced Biological Laboratories (ABL) announced today the CE-IVD marking of its DeepChek®-HIV assays, now available for in-vitro diagnostics.  Intend…

Luxembourg (Luxembourg), Metz (France), Boston (USA) — May 13 — Advanced Biological Laboratories (ABL) announced today that its RT-PCR test for COVID-19 detection UltraGene® Combo2Screen SARS-CoV-2 assay is now officially approved by the French ANSM (Agence nationale de sécurité du médicament) as a…

Luxembourg (Luxembourg), Metz (France), Boston (USA) — May 7— Advanced Biological Laboratories (ABL) announced today the CE-IVD marking of its UltraGene® Combo2Screen SARS-CoV-2 assay is now available for in-vitro diagnostics use. This test is intended to be used for the qualitative detection of nuc…

We did in March 2020 an external clinical validation with the French National Reference Centre for Covid-19 (CNR). The validation was in two phases. Clinical samples were tested both with the CNR’s RT-PCR reference method (IP2/IP4) and the UltraGene Combo2Screen SARS-CoV-2 Assay. The two phase…

NEWBURYPORT, MA – May 1, 2020: AdvancedDx Biological Laboratories USA Inc. (ABLDx), a virologic diagnostic solutions company, announced today its official launch in the U.S. to commercialize solutions that will advance public health in the Americas. The company will be focused on fighting the COVID-…

We are pleased to announce that the UltraGene Combo2Screen SARS-CoV-2 Assay has been validated by the Quality Control for Molecular Diagnostics (QCMD). The QCMD is an independent International External Quality Assessment (EQA) / Proficiency Testing (PT) organisation, providing wide-ranging quality a…

Involved in fight against the new Coronavirus, Covid-19, ABL announces the immediat release of new products :  UltraGene Combo 3 genes CoV-2 Assay : 3 targeted genes : RdRp & N-gene for detection, E-gene for confirmation UltraGene-CoV-2-Combo-2 : 2 targeted genes : RdRp & N-gene  UltraGene E…

ABL is pleased to announce our solutions for Detection – Confirmation – Genotyping of 2019 – nCoV :            

ABL is pleased to announce two major updates on its HIV Genotyping Software applications : the full integration of the ViroScore® and DeepChek® software applications with Nadis the availability of a new web-based and disease-specific chromatogram editor

Meet us at MEDICA 2019 for Leveraging your Infectious Diseases Genotyping Capacities   Good morning, ABL will be attending the next MEDICA forum in Düsseldorf from 18 – 21 November 2019 (Hall 3 / A74).  We will be pleased to have a chance to meet you there and explain you in detail the SA…

FLAGSTAFF, Ariz., and LUXEMBOURG CITY, Luxembourg — Aug. 31 — Advanced Biological Laboratories (ABL) is expected to soon begin manufacturing of a compact, portable and affordable test for tuberculosis (TB), designed by the Translational Genomics Research Institute (TGen), an affiliate of City of Hop…

Nous avons le plaisir de vous annoncer que l’intégration du logiciel ViroScore®-HIV (CE IVD) à la plateforme Nadis est disponible. Cette intégration permet à l’ensemble des utilisateurs Nadis de bénéficier de fonctionnalités avancées pour le génotypage du VIH: Synchronisation bidirectionnelle des do…

Advanced Biological Laboratories (ABL) S.A. and ILC – Hydrox SIA are pleased to announce that they entered into an exclusive distribution agreement of ABL’s Diagnostics line of products, including the DeepChek® Assays and software, in Latvia. See current channel partners.